Document is current
Any future updates will be listed below
-
Authors
Eminovic, Semil https://orcid.org/0009-0001-1871-2976
Lindholz, Maximilian
Dell’Orco, Andrea
Meddeb, Aymen
Baumgärtner, Georg Lukas
Schulze-Weddige, Sophia
Siebert, Eberhard
Wattjes, Mike P.
Penzkofer, Tobias
Nawabi, Jawed
- License Information
-
More Information
Article History
Received: 13 April 2025
Revised: 31 July 2025
Accepted: 2 September 2025
First Online: 17 November 2025
Compliance with ethical standards
:
: The scientific guarantor of this publication is Jawed Nawabi.
: T.P. reports research agreements (no personal payments, outside of the submitted work) with AGO Research GmbH, Aravive, Inc., ARCAGY-GINECO, Astellas Pharma Global Development Inc., AstraZeneca AB, AstraZeneca GmbH, Clovis Oncology, EQRx International, Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline Research & Development Limited, Grupo Español de Investigación en Cáncer de Ovario (GEICO), ImmunoGen Inc, Incyte Corporation, Karyopharm Therapeutics, Mario Negri Gynecology Oncology Group (MaNGO) (111), Merck KGaA, Merck Sharp & Dohme Corp., NOGGO e.V., Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU), Novartis Pharma GmbH, NovoCure GmbH, Sutro Biopharma, Inc., TESARO Inc., TORL Biotherapeutics, LLC, Tubulis GmbH, Universitätspoliklinik A. Gemelli, and Verastem Inc, as well as fees for a book translation (Elsevier) and speaking engagements (Bayer Healthcare). J.N. reports research agreements (no personal payments, outside of submitted work) with Briya Lab Ltd.
: No complex statistical methods were necessary for this paper.
: Written informed consent was waived by the Institutional Review Board.
: Institutional Review Board approval was obtained.
: Some study subjects or cohorts have been previously reported in Meddeb et al [ ].
:
